PRESS RELEASE 9th September 2019
Mogrify appoints Dr. Jane Osbourn, OBE as Chair
Cambridge, UK, 9th September 2019: Mogrify Ltd (Mogrify®), a UK company aiming to transform the development of cell therapies, today announced the appointment of Dr. Jane Osbourn, OBE as Chair of the Board. In addition to this role, Dr. Osbourn will become a Member of the Scientific Advisory Board and support the Company’s executive team in therapeutic program selection, industrial partner development, mentoring and investor relations.
Dr. Osbourn has over 30 years’ experience in biologics discovery and development. Most recently, she was Vice President for Research and Development and Site Leader at MedImmune (AstraZeneca), formerly Cambridge Antibody Technology (CAT), where she contributed to the development of phage display technology. She is a scientific leader in the field of antibody engineering, and has made a significant contribution to the discovery and development of eight marketed drugs (including HUMIRA® and BENLYSTA®) and over 40 clinical candidates. Dr. Osbourn originated several key publications and patents and has presented at a number of parliamentary Select Committees. Dr. Osbourn is also Chair of the Board of Directors of the BioIndustry Association, a Director of Babraham Bioscience Technologies, a Director of Cambridge Enterprise and was awarded an OBE this year for services to drug discovery, development and biotechnology. She holds a doctorate from the John Innes Institute in Norwich, UK and a first-class degree in natural sciences from the University of Cambridge.
Dr. Darrin M. Disley, OBE, CEO, Mogrify, said: “Dr. Osbourn is an inspirational leader in our industry who has developed numerous life-saving therapies and is renowned for her expertise in drug discovery and development among the global biotech and pharma communities. As Chair, her guidance will be invaluable to Mogrify as we build a scalable infrastructure and the capability to develop novel cell therapies addressing musculoskeletal, auto-immune, cancer immunotherapy, ocular and respiratory diseases as well as generating and licensing novel IP related to cell conversions that exhibit safety, efficacy and scalable manufacturing profiles suitable for development as cell therapies.”
Dr. Jane Osbourn, OBE, Chair, Mogrify, said: “Mogrify’s leadership team is of high commercial and scientific caliber; it was founded by leading academics in bioinformatics, machine learning and cell reprograming, and the Company has continued to strengthen its management and scientific teams with its recent move to state-of-the-art facilities on Cambridge Science Park. Mogrify’s platform has the ability to address many of the current challenges of cell therapy, which is an area of significant innovation and opportunity, and I am very excited to join the Company at this stage in its development and look forward to its continued success.”
For further information about Mogrify’s team, please visit: www.mogrify.co.uk/board-of-directors
Notes to Editors
Dr. Jane Osbourn, OBE
Chair – Mogrify
For high-resolution and alternate images please contact Zyme Communications.
For further information please contact:
Darrin M Disley, PhD, OBE
Tel: + 44 (0)1223 734154
Tel: +44 (0)7811 996 942
About Mogrify www.mogrify.co.uk
Mogrify has developed a proprietary direct cellular conversion technology, which makes it possible to transform (transmogrify) any mature human cell type into any other without going through a pluripotent stem cell- or progenitor cell-state.
The platform takes a systematic big-data approach to identify, from next-generation sequencing and gene-regulatory networks, the transcription factors (in vitro) or small molecules (in vivo), needed to convert a cell. By bypassing the stem cell-stage of cell transformation, Mogrify simultaneously addresses challenges associated with efficacy, safety and scalability.
Mogrify is deploying this platform to develop novel cell therapies addressing musculoskeletal, autoimmune, cancer immunotherapy, ocular and respiratory diseases as well as generating a broad IP position relating to cell conversions that exhibit safety, efficacy and scalable manufacturing profiles suitable for development as cell therapies.
Uniquely positioned to address a cell therapy market estimated to be $35 billion USD by 2023, Mogrify is commercializing its technology via IP licensing, product development, and drug development. Based in Cambridge, UK, the Company has raised significant funding from Ahren Innovation Capital, 24Haymarket and Dr. Darrin M. Disley, OBE.